TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26474174

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus icotinib (125 mg thrice daily for 4-8 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 41
Study: 23577773

Group type: EXPERIMENTAL
Intervention: Minimal stimulation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low frequency stimulation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Standard stimulation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Permanent system placement
Number of subjects: 44
Study: 21263367

Group type: EXPERIMENTAL
Intervention: Intermittent propofol sedation (bolus of 2-4 mg/kg, followed by repeat boluses of 0.5-2 mg/kg/dose as needed)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Continuous propofol sedation (bolus of 2-4 mg/kg, followed by continuous infusion of 100 μg/kg/min with 1-mg/kg/dose boluses)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups (intermittent and continuous)
Number of subjects: 170
Study: 19100061

Group type: EXPERIMENTAL
Intervention: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in DCM patients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in healthy adults
Number of subjects: 90
Study: 15790932

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colestimide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12883406

Group type: EXPERIMENTAL
Intervention: Sufentanil effect site concentration of 0.5 ng/ml (group 1)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sufentanil effect site concentration of 1.25 ng/ml (group 4)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Propofol concentration adjusted based on BIS values
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sufentanil concentrations
Number of subjects: 110

Group type: COMPARATOR
Intervention: Mean arterial pressure, heart rate, time to tracheal extubation, awareness, satisfaction scores, morphine requirements
Number of subjects: 110
Study: 10786240

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mothers of schizophrenic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 8874444

Group type: EXPERIMENTAL
Intervention: YAG laser iridotomy in one eye
Number of subjects: 21

Group type: COMPARATOR
Intervention: No intervention in the fellow eye (control)
Number of subjects: 21
Study: 2054278

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 4 mg with paracetamol 650 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6393937

Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rectal metronidazole
Number of subjects: 0
Study: 31303389

Group type: EXPERIMENTAL
Intervention: Acupressure on four different acupoints plus standard care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 29384326

Group type: EXPERIMENTAL
Intervention: 75‐g 2‐h oral glucose tolerance test (OGTT)
Number of subjects: 4959

Group type: EXPERIMENTAL
Intervention: Advanced maternal age
Number of subjects: 4959

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy body mass index (overweight)
Number of subjects: 4959

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy body mass index (obesity)
Number of subjects: 4959

Group type: EXPERIMENTAL
Intervention: Paternal history of diabetes
Number of subjects: 4959

Group type: EXPERIMENTAL
Intervention: Maternal history of diabetes
Number of subjects: 4959
Study: 27102653

Group type: EXPERIMENTAL
Intervention: School-based intervention program
Number of subjects: 1440
Study: 25197908

Group type: EXPERIMENTAL
Intervention: Real ear acupressure (EAP) treatment
Number of subjects: 245

Group type: COMPARATOR
Intervention: Sham ear acupressure (EAP) treatment
Number of subjects: 245
Study: 22697191

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 21187618

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5.25% sodium hypochlorite solution
Number of subjects: 40
Study: 18776075

Group type: EXPERIMENTAL
Intervention: Home telemonitoring-based care
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 16550876

Group type: EXPERIMENTAL
Intervention: Viscoelastic with anesthetic (sodium hyaluronate 1.5% and lidocaine 1%)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Viscoelastic without anesthetic
Number of subjects: 874
Study: 12208796

Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Antibiotics (both regimens)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 10512922

Group type: EXPERIMENTAL
Intervention: Number of small (<3 mm) basal ganglia lesions
Number of subjects: 3660

Group type: EXPERIMENTAL
Intervention: White matter grade
Number of subjects: 3660

Group type: EXPERIMENTAL
Intervention: Logistic regression models controlling for non-MRI variables and severity of white matter lesions
Number of subjects: 3660
Study: 7851677

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 260

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 260
Study: 1823064

Group type: EXPERIMENTAL
Intervention: Pentagastrin (6 micrograms/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ranitidine injection (5 minutes before pentagastrin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ranitidine injection (1 hour before pentagastrin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham feeding
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short-term oral intake of ranitidine
Number of subjects: 20
Study: 7274006

Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (bed rest)
Number of subjects: 0
Study: 31432689

Group type: EXPERIMENTAL
Intervention: Neratinib-based therapy
Number of subjects: 271
Study: 30118784

Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen (NCK) Program, 6-week duration, 3 hours weekly, including hands-on cooking classes and a food market visit
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen (NCK) Program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 76
Study: 26952222

Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion at a rate of 1.5mg/kg/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV esmolol infusion at a rate of 1mg/kg/min
Number of subjects: 60
Study: 25223462

Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 371

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 371
Study: 22294563

Group type: EXPERIMENTAL
Intervention: 6-PACK programme (nurse delivered falls prevention programme)
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Usual care practice (control group)
Number of subjects: 16000
Study: 20388562

Group type: EXPERIMENTAL
Intervention: Partial rectal wall advancement flap (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mucosal advancement flap (Group II)
Number of subjects: 40
Study: 18821872

Group type: EXPERIMENTAL
Intervention: Treatment for alcohol dependence (details on specific medications or behavioral interventions not provided)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Treatment for alcohol dependence
Number of subjects: 1383
Study: 16763371

Group type: EXPERIMENTAL
Intervention: Urinary proteomic analysis using SELDI‐MS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Classification of patients as SSNS or SRNS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Identification of a protein of mass 4,144 daltons
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SELDI‐MS combined with bioinformatics
Number of subjects: 42
Study: 12795130

Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of bupivacaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous extradural infusion of morphine
Number of subjects: 10
Study: 10563213

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8733681

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (standard anti-emetics)
Number of subjects: 58
Study: 1761451

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 65
Study: 6349743

Group type: EXPERIMENTAL
Intervention: Combination of emepronium bromide and flavoxate hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30419226

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg, 3 times daily, started 4 hours before the ascent)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Acetazolamide (125 mg, twice daily, started the night before the ascent)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 92

Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 92
Study: 30206346

Group type: EXPERIMENTAL
Intervention: Restricted fluid intake (two-thirds of normal intake)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal fluid intake
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Restricted fluid intake
Number of subjects: 80
Study: 28462933

Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy (group‐CBT) added to standard spinal cord injury inpatient rehabilitation (SR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard spinal cord injury inpatient rehabilitation (SR) without group‐CBT
Number of subjects: 50
Study: 25613747

Group type: EXPERIMENTAL
Intervention: Intravenous GIP (4 pmol/kg/min)
Number of subjects: 20
Study: 22447467

Group type: EXPERIMENTAL
Intervention: Candesartan, 12 mg monotherapy (group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ), 6.25 mg in combination with candesartan, 8 mg (group B)
Number of subjects: 26
Study: 20933098

Group type: EXPERIMENTAL
Intervention: MRI group (n = 258)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Control group (n = 206)
Number of subjects: 464
Study: 19000959

Group type: EXPERIMENTAL
Intervention: Telemedicine group (TmG) - patient-GP short-messages-based interaction
Number of subjects: 285
Study: 16998171

Group type: EXPERIMENTAL
Intervention: Active nicotine patches (6-week reducing dose regimen)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 14587237

Group type: EXPERIMENTAL
Intervention: Microsatellite analysis using LOH/MSI in exfoliated cells from urinary sediment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Urinary cytology
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Microsatellite alterations in superficial tumors
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: D4S243 microsatellite marker
Number of subjects: 160
Study: 11898235

Group type: EXPERIMENTAL
Intervention: Aerobic exercise during chemotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-exercisers (control group)
Number of subjects: 78
Study: 9366671

Group type: EXPERIMENTAL
Intervention: Optic neuritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterior ischemic optic neuropathy
Number of subjects: 0
Study: 8466240

Group type: EXPERIMENTAL
Intervention: Protein restricted diet (0.8‐1.1 g/kg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 4003187

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30824408

Group type: EXPERIMENTAL
Intervention: Alkylating agents (ALKY)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oxaliplatin-based chemotherapy (Ox)
Number of subjects: 104
Study: 29106669

Group type: EXPERIMENTAL
Intervention: E-cigarette ads with high youth appeal
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: E-cigarette ads with low youth appeal
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control ads
Number of subjects: 417
Study: 26847219

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (no hypnosis)
Number of subjects: 171
Study: 25667123

Group type: EXPERIMENTAL
Intervention: Achillea millefolium distillate solution (15 mL gargled 4 times a day for 14 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine solution (15 mL gargled 4 times a day for 14 days)
Number of subjects: 56
Study: 22141591

Group type: EXPERIMENTAL
Intervention: Melatonin plus common sedation and analgesia (atropine, fentanyl, vecuronium)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Common sedation and analgesia (atropine, fentanyl, vecuronium)
Number of subjects: 60
Study: 20354490

Group type: EXPERIMENTAL
Intervention: abciximab plus a sirolimus coated stent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: abciximab plus a bare stent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: abciximab plus PTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sirolimus coated stent
Number of subjects: 60
Study: 18518674

Group type: EXPERIMENTAL
Intervention: autologous periosteal cells in a fibrin/polyglactin-poly-p-dioxanone fleece
Number of subjects: 24

Group type: COMPARATOR
Intervention: autologous iliac crest cancellous bone
Number of subjects: 24
Study: 16873950

Group type: EXPERIMENTAL
Intervention: 200 mg coenzyme Q(10) soft oil capsules
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg coenzyme Q(10) soft oil capsules
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 mg crystalline Q(10) powder capsules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11934231

Group type: EXPERIMENTAL
Intervention: PulmoSphere particles (99mTc‐radiolabeled)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Evohaler pMDI (micronized particles)
Number of subjects: 9
Study: 10075336

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified biscuits (fortified with iron, iodine, and beta-carotene) consumed for 43 weeks over a 12-month period
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified biscuits
Number of subjects: 115

Group type: COMPARATOR
Intervention: Nonfortified biscuits (control group)
Number of subjects: 115
Study: 9150971

Group type: EXPERIMENTAL
Intervention: Acute psychological stress test (mirror drawing, watching horror video, arithmetic under intermittent noise)
Number of subjects: 43
Study: 1922205

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: Exercise plus dietary calcium supplementation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Exercise plus continuous replacement of estrogen and progesterone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (normal bone density)
Number of subjects: 120
Study: 387704

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Clindamycin plus cephaloridine
Number of subjects: 230

Group type: COMPARATOR
Intervention: Cephaloridine
Number of subjects: 230
Study: 31989684

Group type: EXPERIMENTAL
Intervention: Closed-loop system
Number of subjects: 22
Study: 31107133

Group type: EXPERIMENTAL
Intervention: Anterior tympanomeatal flap elevation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Posterior tympanomeatal flap elevation
Number of subjects: 26
Study: 28002096

Group type: EXPERIMENTAL
Intervention: 60 mg duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25836698

Group type: EXPERIMENTAL
Intervention: Optimisation group (B) - CT pitch increment and lowering tube current
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (A) - standard CT examination
Number of subjects: 50
Study: 23803687

Group type: EXPERIMENTAL
Intervention: Communication partner training (JOINT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Individual treatment (TBI SOLO)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study: 17721974

Group type: EXPERIMENTAL
Intervention: Adult sexual abuse (ASA) group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-adult sexual abuse (non-ASA) group
Number of subjects: 69
Study: 15041924

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New methods improving specificity and sensitivity of PSA test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New molecular forms of PSA (PSA isoforms)
Number of subjects: 0
Study: 10845900

Group type: EXPERIMENTAL
Intervention: Blood stem cell transplantation
Number of subjects: 824

Group type: COMPARATOR
Intervention: Bone marrow transplantation
Number of subjects: 824
Study: 9354315

Group type: EXPERIMENTAL
Intervention: Frusemide + Meloxicam (15 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Frusemide (Control)
Number of subjects: 19
Study: 8408734

Group type: EXPERIMENTAL
Intervention: Felodipine (7.5 micrograms/min for 30 minutes followed by 5 micrograms/min for 120 minutes)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 11
Study: 3006414

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg bolus in 20 ml normal saline)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 6
Study: 31010499

Group type: EXPERIMENTAL
Intervention: Single preoperative pain neuroscience education (PNE) session plus therapeutic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard preoperative care plus therapeutic exercise
Number of subjects: 0
Study: 28029752

Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 301
Study: 26801163

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 120
Study: 24946562

Group type: EXPERIMENTAL
Intervention: Compound Wuzhigan capsules (2 capsules one time, three times a day for 3 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Compound Wuzhigan tablets (4 tablets one time, three times a day for 3 days)
Number of subjects: 120
Study: 22001942

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg for 8 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg for 4 weeks
Number of subjects: 112
Study: 19223667

Group type: EXPERIMENTAL
Intervention: Accelerated reading training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Unaccelerated reading training
Number of subjects: 59
Study: 17258926

Group type: EXPERIMENTAL
Intervention: Intensive multitherapy (IMT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 15100501

Group type: EXPERIMENTAL
Intervention: F-FDG PET
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 26
Study: 12139561

Group type: EXPERIMENTAL
Intervention: Oropharyngeal cultures from healthy infants and children
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Attendance at day-care centers (DCC)
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Attendance at elementary schools (ES)
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Hib isolates susceptibility testing
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of predictors
Number of subjects: 1404
Study: 9814473

Group type: EXPERIMENTAL
Intervention: Human CG (10 U/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-1 (10 ng/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interleukin (IL)-4 (10 ng/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interleukin (IL)-10 (10 ng/mL)
Number of subjects: 0
Study: 7649498

Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cyclandelate and Propranolol
Number of subjects: 84
Study: 2468927

Group type: COMPARATOR
Intervention: Atenolol (1, 1, 2, and 4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cicloprolol (0.025, 0.025, 0.05, and 0.1 mg/kg)
Number of subjects: 24
Study: 7095

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg) + Flunitrazepam (2 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg)
Number of subjects: 140
Study: 31456003

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (RT) with single doses of 0.5Gy (total dose 3.0-5.0Gy)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (RT)
Number of subjects: 598
Study: 28711972

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 1441
Study: 25868059

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate containing 50 mg zinc)
Number of subjects: 52
Study: 23892423

Group type: EXPERIMENTAL
Intervention: Protocol for management of interval appendectomy
Number of subjects: 45
Study: 22509642

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (5 doses of 2.5 ml each, one dose per week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylprednisolone (single 2 ml dose)
Number of subjects: 40